2021 CMSC Annual Meeting

Go back to the CMSC Education Website
Search

Tag: CO

Poster-Non-imaging Biomarkers

October 25, 2021

Concentration of Evobrutinib, a Bruton’s Tyrosine Kinase Inhibitor, in Cerebrospinal Fluid during Treatment of Patients with Relapsing Multiple Sclerosis in a Phase 2 Study

Background: Evobrutinib, a highly selective Bruton’s tyrosine kinase (BTK) inhibitor, demonstrated a low annualized relapse rate (75mg...

Read More →

Poster-Internet and Information Services

October 25, 2021

MS and COVID-19: A Webinar Series for Healthcare Providers

Background: MS is a complex disease that requires a well- educated workforce. The COVID-19 pandemic added to that complexity- from the lack...

Read More →

Poster-Disease-modifying Therapy

October 25, 2021

Agnos Study Design: A Phase 4 Study Assessing Ofatumumab in Treatment-Naïve Young Adults with Early Relapsing Remitting MS Benchmarked Against Healthy Controls

Background: Early intervention with high efficacy therapies has been shown to reduce long-term disability accrual in patients with multiple...

Read More →

Poster-Disease-modifying Therapy

October 25, 2021

Olikos Study Design: Exploring Maintained Ofatumumab Efficacy in Relapsing MS Patients Who Transition from Intravenous Anti-CD20 Therapy

Background: B-cell depletion in patients with relapsing multiple sclerosis (RMS) using anti-CD20 monoclonal antibodies (mAbs) reduces...

Read More →

Poster-Disease-modifying Therapy

October 25, 2021

Real-World Cost of Care, Treatment Completion and Site of Care Cost for Patients with Multiple Sclerosis Initiating Infused Disease-Modifying Therapies

Background: Expenditures for intravenous (IV) disease-modifying therapies (DMTs) for multiple sclerosis (MS) include costs beyond wholesale...

Read More →

Poster-Disease-modifying Therapy

October 25, 2021

Adherence to Multiple Sclerosis Disease Modifying Therapies Using Pharmacy Quality Alliance Criteria and Medical Costs or Hospitalizations in an Administrative Database.

Background: Evidence is needed that adherence to disease-modifying therapies (DMT) for multiple sclerosis (MS) can reduce total medical...

Read More →

Poster-Disease-modifying Therapy

October 25, 2021

Click-MS: Cladribine Tablets in Patients with Relapsing Multiple Sclerosis after Suboptimal Response to Prior Injectable Disease-Modifying Therapy (Interim Analysis 1)

Background: The efficacy and safety of cladribine tablets 3.5 mg/kg (cumulative dose over 2 years) have been shown in patients with...

Read More →

Poster-Disease-modifying Therapy

October 25, 2021

Multiple Sclerosis Disease Modifying Therapies’ Adherence and Total Medical Costs Among Women with Maternity Services Using Administrative Data.

Background: Women with multiple sclerosis (MS) who become pregnant and utilize maternity services may find their use of disease-modifying...

Read More →

Poster-Disease-modifying Therapy

October 25, 2021

Recently Diagnosed Treatment-Naive RRMS: 1-Year Safety Data from the Ocrelizumab Phase IIIb ENSEMBLE Study

Background: ENSEMBLE (NCT03085810) is a multicenter, open-label, single-arm Phase IIIb study evaluating the effectiveness and safety of...

Read More →

Platform-Disease Management

October 25, 2021

Development and Usability Testing of a Patient-Based Digital Tool to Detect Early Signs of Changes in Multiple Sclerosis Symptoms and Progression: Your MS Questionnaire

Background: The validated physician-completed MSProDiscussTM tool facilitates physician-patient interaction in evaluating early signs of...

Read More →
MAILING ADDRESS

3 University Plaza Drive, Ste 116
Hackensack, NJ 07601

CONTACT US

(201) 487-1050
info@mscare.org

FOLLOW US
Facebook-f Twitter Linkedin Youtube

© 2021 CMSC